Demystifying Moderna: Insights From 16 Analyst Reviews

Demystifying Moderna: Insights From 16 Analyst Reviews

1 day from now

Nov 15, 2024  · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a high estimate of $139.00, and a low estimate …

benzinga.com

16 Analysts Have This To Say About Moderna - Benzinga

1 day from now

Sep 13, 2024  · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $111.5, along with a high estimate of $214.00 and a low …

benzinga.com

Demystifying Moderna: Insights From 11 Analyst Reviews

1 day from now

Aug 15, 2024  · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $140.55, with a high estimate of $214.00 and a low estimate …

nasdaq.com

In-Depth Examination Of 15 Analyst Recommendations For Moderna

1 day from now

Nov 4, 2024  · Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.4, a high estimate of $139.00, and a low estimate of $55.00.

benzinga.com

Unveiling 18 Analyst Insights On Moderna - Nasdaq

1 day from now

Oct 15, 2024  · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $102.44, a high estimate of $178.00, and a low estimate of $55.00.

nasdaq.com

Breaking Down Moderna: 7 Analysts Share Their Views

1 day from now

Jun 3, 2024  · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $132.14, with a high estimate of $163.00 and a low estimate of $106.00.

nasdaq.com

StockWatch: Analysts Mixed On Moderna Despite $750M …

1 day from now

Apr 1, 2024  · Analysts have been decidedly mixed in their assessment of Moderna. On the bullish side, Jefferies analyst Michael Yee raised his firm’s 12-month price target on Moderna shares …

genengnews.com

Moderna: Shares Remain Deeply Undervalued, Despite Our Lower …

1 day from now

Oct 16, 2023  · That said, we’re lowering our fair value estimate for Moderna from $266.00 to $227.00, as we now assume demand for COVID-19 vaccines will remain at these trough levels …

morningstar.com

Moderna Surges 14% After Covid Vaccine-Maker Surprises With …

1 day from now

Feb 22, 2024  · Moderna stock analysts model $321 million in sales of the company's vaccine this year. Mock notes Moderna's shot uses a pre-filled syringe, which could help it gain share from …

investors.com

Demystifying NEXTracker: Insights From 11 Analyst Reviews

1 day from now

Nov 19, 2024  · Analysts have recently evaluated NEXTracker and provided 12-month price targets. The average target is $50.91, accompanied by a high estimate of $58.00 and a low …

nasdaq.com

Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst …

1 day from now

Sep 19, 2024  · The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of $600.00, and a low estimate of $376.00.

nasdaq.com

Moderna's 6-month Review Of COVID-19 Vaccine Post Dose 2 …

1 day from now

Apr 14, 2021  · Drive Growth with Insights Asset Owner Solutions; Asset Manager Solutions ... Moderna's 6-month Review Of COVID-19 Vaccine Post Dose 2 Shows More Than 90% …

nasdaq.com

Demystifying Merck & Co: Insights From 8 Analyst Reviews

1 day from now

Oct 3, 2024  · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, a high estimate of $155.00, and a low …

nasdaq.com

15 Analysts Assess Tenet Healthcare: What You Need To Know

1 day from now

Oct 1, 2024  · Insights from analysts' 12-month price targets are revealed, presenting an average target of $162.6, a high estimate of $197.00, and a low estimate of $112.00.

nasdaq.com